[1]金 英.甲磺酸伊马替尼对难治性Ph染色体阳性急性淋巴细胞白血病患者免疫功能及生存率的影响[J].医学信息,2022,35(13):139-141.[doi:10.3969/j.issn.1006-1959.2022.13.033]
　JIN Ying.Effect of Imatinib Mesylate on Immune Function and Survival Rate in Patients with Refractory Ph Chromosome Positive Acute Lymphoblastic Leukemia[J].Medical Information,2022,35(13):139-141.[doi:10.3969/j.issn.1006-1959.2022.13.033]
点击复制

甲磺酸伊马替尼对难治性Ph染色体阳性急性淋巴细胞白血病患者免疫功能及生存率的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年13期
页码:
139-141
栏目:
论著
出版日期:
2022-07-01

文章信息/Info

Title:
Effect of Imatinib Mesylate on Immune Function and Survival Rate in Patients with Refractory Ph Chromosome Positive Acute Lymphoblastic Leukemia
文章编号:
1006-1959（2022）13-0139-03
作者:
金 英
（佳木斯市中心医院血液内科，黑龙江 佳木斯 154002）
Author(s):
JIN Ying
(Department of Hematology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
Ph染色体阳性; 急性淋巴细胞白血病; 甲磺酸伊马替尼; 免疫功能; 总生存时间
Keywords:
Ph chromosome positive; Acute lymphoblastic leukemia; Imatinib mesylate; Immune function; Total survival time
分类号:
R733.71
DOI:
10.3969/j.issn.1006-1959.2022.13.033
文献标志码:
A
摘要:
目的 探讨甲磺酸伊马替尼对难治性Ph染色体阳性急性淋巴细胞白血病患者的免疫功能及生存率的影响。方法 选取我院2017年6月-2020年11月收治的难治性Ph染色体阳性急性淋巴细胞白血病患者72例，采用随机数表法随机分为对照组与联合治疗组，各36例。对照组患者予以常规化疗，联合治疗组在对照组基础上加用甲磺酸伊马替尼治疗。比较两组T细胞免疫功能、完全缓解（CR）率、生存（OS）时间、无复发生存（RFS）时间及不良反应发生情况。结果 联合治疗组治疗后CD3+、CD4+、CD4+/CD8+水平均高于对照组，差异有统计学意义（P＜0.05）；联合治疗组完全缓解率为88.89%、中位生存时间为30.63个月、中位无复发生存时间为25.12个月，均高于对照组的38.89%、11.62个月及9.64个月，差异有统计学意义（P＜0.05）；联合治疗组不良反应总发生率为16.67%，低于对照组的58.33%，差异有统计学意义（P＜0.05）。结论 甲磺酸伊马替尼用于治疗难治性Ph染色体阳性急性淋巴细胞白血病疾病能有效改善患者免疫功能，延长患者无复发生存时间和总生存时间，且用药安全性较高。
Abstract:
Objective To investigate the effect of imatinib mesylate on immune function and survival rate in patients with refractory Ph chromosome positive acute lymphoblastic leukemia.Methods A total of 72 patients with refractory Ph chromosome positive acute lymphoblastic leukemia admitted to our hospital from June 2017 to November 2020 were randomly divided into control group and combined treatment group, with 36 cases in each group. Patients in the control group were treated with conventional chemotherapy, while patients in the combined treatment group were treated with imatinib mesylate on the basis of the control group. T cell immune function, complete remission (CR) rate, survival (OS) time, non-recurrence survival (RFS) time and incidence of adverse reactions were compared between the two groups.Results After treatment, the levels of CD3+, CD4+ and CD4+/CD8+ in the combined treatment group were higher than those in the control group, and the difference was statistically significant (P<0.05). The complete remission rate, median survival time and median recurrence-free survival time of the combined treatment group were 88.89%, 30.63 months and 25.12 months, which were higher than 38.89%, 11.62 months and 9.64 months of the control group, and the differences were statistically significant (P<0.05). The total incidence of adverse reactions in the combined treatment group was 16.67%, which was lower than 58.33% in the control group, and the difference was statistically significant (P<0.05).Conclusion Imatinib mesylate for the treatment of refractory Ph chromosome positive acute lymphoblastic leukemia can effectively improve the immune function of patients, prolong the recurrence free survival time and overall survival time of patients, and the drug safety is high.

参考文献/References:

[1]Fujita TC,Sousa-Pereira N,Amarante MK.Acute lymphoid leukemia etiopathogenesis[J].Mol Biol Rep,2021,48(1):817-822.[2]Kim J,Lee DH,Badamtsetseg B.Anti-Proliferative Effect of Allium senescens L.Extract in Human T-Cell Acute Lymphocytic Leukemia Cells[J].Molecules,2020,26(1):35.[3]王欣玉,常英军,刘艳荣.多参数流式细胞术与实时定量PCR技术检测Ph阳性急性B淋巴细胞白血病异基因造血干细胞移植前微小残留病的预后意义比较[J].中华血液学杂志,2021,42(2):116-123.[4]Chiaretti S,Messina M,Foà R.BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?[J].Cancer,2019,125(2):194-204.[5]Abou Dalle I,Jabbour E,Short NJ.Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia[J].Curr Treat Options Oncol,2019,20(1):4.[6]吴健晖,林丽娥.甲磺酸伊马替尼(格列卫)治疗晚期慢性粒细胞性白血病的临床疗效观察[J].中国医院药学杂志,2012,32(7):522-524.[7]Nayeem MJ,Yamamura A,Hayashi H.Imatinib mesylate inhibits androgen-independent PC-3 cell viability, proliferation, migration, and tumor growth by targeting platelet-derived growth factor receptor-α[J].Life Sci,2021,288:120171.[8]Advani AS,Tse W,Li H.A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia[J]. Clin Lymphoma Myeloma Leuk,2021,21(2):113-118.[9]李娟,张志彪,刘峥嵘,等.87例成人Ph染色体阴性ALL预后影响因素分析[J].中国实验血液学杂志,2018,26(4):1011-1015.[10]Pui CH.Precision medicine in acute lymphoblastic leukemia[J].Front Med,2020,14(6):689-700.[11]Soverini S,Bassan R,Lion T.Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges[J].J Hematol Oncol,2019,12(1):39.[12]Asnafi AA,Deris Zayeri Z,Shahrabi S.Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches[J].J Cell Physiol,2019,234(5):5798-5806.[13]Ｉ?觭?觟z K,Eken A,Cinar S,et al.Immunomagnetic separation of B type acute lymphoblastic leukemia cells from bone marrow with flow cytometry validation and microfluidic chip measurements[J].Separation Science and Technology,2021,56(15):2659-2666.[14]Topp MS,G?觟kbuget N,Zugmaier G.Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab[J].Cancer,2021,127(4):554-559.[15]Ronicke M,Erfurt-Berge C.Impaired Wound Healing with Imatinib Mesylate Therapy[J].Adv Skin Wound Care,2021,34(2):109-111.[16]时海荣,肖丁华,刘冯,等.急性淋巴细胞白血病合并EB病毒感染1年生存影响因素[J].中华医院感染学杂志,2021,31(14):2169-2173.[17]Tasian SK,Loh ML,Hunger SP.Philadelphia chromosome-like acute lymphoblastic leukemia[J].Blood,2017,130(19):2064-2072.[18]Pommert L,Liberio N,Ng JS.Concurrent Imatinib Dosing With High-dose Methotrexate Leads to Acute Kidney Injury and Delayed Methotrexate Clearance in Pediatric Patients With Philadelphia Chromosome-positive B-Cell Acute Lymphoblastic Leukemia[J].J Pediatr Hematol Oncol,2021,43(2):e296-e300.[19]吴崇军,陈峰,叶瑶,等.13例Ph染色体阳性儿童急性淋巴细胞白血病临床分析[J].江西医药,2021,56(2):165-167,180.[20]Suttorp M,Metzler M,Millot F.Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients[J].Pediatr Blood Cancer,2018,65(12):e27431.

相似文献/References:

[1]黄倩云,李长钢.门冬酰胺酶对白血病患儿静脉血栓形成的研究进展[J].医学信息,2018,31(12):39.[doi:10.3969/j.issn.1006-1959.2018.12.013]
　HUANG Qian-yun,LI Chang-gang.Advances in the Treatment of Venous Thrombosis in Children with Leukemia by Asparaginase[J].Medical Information,2018,31(13):39.[doi:10.3969/j.issn.1006-1959.2018.12.013]
[2]韩怡波.儿童急淋大剂量甲氨蝶呤延迟解救的安全性研究[J].医学信息,2019,32(19):143.[doi:10.3969/j.issn.1006-1959.2019.19.046]
　HAN Yi-bo.Safety Study on Delayed Rescue of High-Dose Methotrexate in Children[J].Medical Information,2019,32(13):143.[doi:10.3969/j.issn.1006-1959.2019.19.046]
[3]杨月琴,叶中绿.儿童急性淋巴细胞白血病早期治疗反应对预后价值的研究[J].医学信息,2020,33(04):51.[doi:10.3969/j.issn.1006-1959.2020.04.016]
　YANG Yue-qin,YE Zhong-lv.Study on Early Prognostic Value of Childhood Acute Lymphoblastic Leukemia in Response to Treatment[J].Medical Information,2020,33(13):51.[doi:10.3969/j.issn.1006-1959.2020.04.016]
[4]刘婕妤,方智辉,李文克,等.复方磺胺甲噁唑对急性淋巴细胞白血病化疗后肺孢子菌肺炎的预防作用[J].医学信息,2020,33(12):135.[doi:10.3969/j.issn.1006-1959.2020.12.042]
　LIU Jie-yu,FANG Zhi-hui,LI Wen-ke,et al.Preventive Effect of Compound Sulfamethoxazole on Pneumocystis Pneumonia After Chemotherapy in Acute Lymphoblastic Leukemia[J].Medical Information,2020,33(13):135.[doi:10.3969/j.issn.1006-1959.2020.12.042]
[5]孙 燕,王绪栋,王兆辉,等.伴t(2;13)(q11;p11)特殊易位的儿童急性淋巴细胞白血病反复复发1例报道[J].医学信息,2021,34(20):190.[doi:10.3969/j.issn.1006-1959.2021.20.053]

更新日期/Last Update: 1900-01-01